Browsing ICR Divisions by author "Shepherd, Scott"
Now showing items 1-11 of 11
-
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27) -
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27)Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients ... -
Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
Au, L; Fendler, A; Shepherd, STC; Rzeniewicz, K; Cerrone, M; et al. (NATURE PORTFOLIO, 2021-05-26)Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported ... -
Deciphering evolutionary trajectories in hereditary renal cell carcinomas
Turajlic S; Shepherd, S; Turajlic, S (Institute of Cancer Research (University Of London), 2024-01-16)Establishing the limits of predictability in cancer evolution has significant implications for precision medicine. Clear cell renal cell carcinoma (ccRCC) follows highly deterministic evolutionary pattern with conserved ... -
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Au, L; Hatipoglu, E; Robert de Massy, M; Litchfield, K; Beattie, G; et al. (CELL PRESS, 2021-11-08)ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the mechanism ... -
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
Fendler, A; Au, L; Shepherd, STC; Byrne, F; Cerrone, M; et al. (NATURE PORTFOLIO, 2021-09-20)Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were ... -
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.
Fendler, A; Shepherd, STC; Au, L; Wu, M; Harvey, R; et al. (CELL PRESS, 2022-10-18)Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we ... -
Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.
Spain, L; Coulton, A; Lobon, I; Rowan, A; Schnidrig, D; et al. (AMER ASSOC CANCER RESEARCH, 2023-06-02)UNLABELLED: Understanding the evolutionary pathways to metastasis and resistance to immune-checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here, we present the most comprehensive intrapatient ... -
Selection of metastasis competent subclones in the tumour interior.
Zhao, Y; Fu, X; Lopez, JI; Rowan, A; Au, L; et al. (NATURE PORTFOLIO, 2021-05-17)The genetic evolutionary features of solid tumour growth are becoming increasingly well described, but the spatial and physical nature of subclonal growth remains unclear. Here, we utilize 102 macroscopic whole-tumour ... -
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.
Wu, MY; Shepherd, STC; Fendler, A; Carr, EJ; Au, L; et al. (CELL PRESS, 2023-05-08)Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants. -
Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study.
Fu, X; Zhao, Y; Lopez, JI; Rowan, A; Au, L; et al. (NATURE PORTFOLIO, 2022-01-01)Genetic intra-tumour heterogeneity fuels clonal evolution, but our understanding of clinically relevant clonal dynamics remain limited. We investigated spatial and temporal features of clonal diversification in clear cell ...